Foxp3 Antibody - #AF6544

(6)   (6)  
Product: Foxp3 Antibody
Catalog: AF6544
Description: Rabbit polyclonal antibody to Foxp3
Application: WB IHC IF/ICC
Reactivity: Human, Mouse, Rat
Mol.Wt.: 47kDa; 47kD(Calculated).
Uniprot: Q9BZS1
RRID: AB_2847268

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
IF/ICC 1:100-1:500, WB 1:500-1:2000, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Clonality:
Polyclonal
Specificity:
Foxp3 Antibody detects endogenous levels of total Foxp3.
RRID:
AB_2847268
Cite Format: Affinity Biosciences Cat# AF6544, RRID:AB_2847268.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

AIID; DIETER; Forkhead box P3; Forkhead box protein P3; FOXP3; FOXP3_HUMAN; FOXP3delta7; Immune dysregulation polyendocrinopathy enteropathy X linked; Immunodeficiency polyendocrinopathy enteropathy X linked; IPEX; JM2; MGC141961; MGC141963; OTTHUMP00000025832; OTTHUMP00000025833; OTTHUMP00000226737; PIDX; Scurfin; XPID;

Immunogens

Immunogen:

A synthesized peptide derived from human Foxp3.

Uniprot:

Q9BZS1(FOXP3_HUMAN) >>Visit HPA database.

Gene(ID):
FOXP3(50943)
Sequence:
MPNPRPGKPSAPSLALGPSPGASPSWRAAPKASDLLGARGPGGTFQGRDLRGGAHASSSSLNPMPPSQLQLPTLPLVMVAPSGARLGPLPHLQALLQDRPHFMHQLSTVDAHARTPVLQVHPLESPAMISLTPPTTATGVFSLKARPGLPPGINVASLEWVSREPALLCTFPNPSAPRKDSTLSAVPQSSYPLLANGVCKWPGCEKVFEEPEDFLKHCQADHLLDEKGRAQCLLQREMVQSLEQQLVLEKEKLSAMQAHLAGKMALTKASSVASSDKGSCCIVAAGSQGPVVPAWSGPREAPDSLFAVRRHLWGSHGNSTFPEFLHNMDYFKFHNMRPPFTYATLIRWAILEAPEKQRTLNEIYHWFTRMFAFFRNHPATWKNAIRHNLSLHKCFVRVESEKGAVWTVDELEFRKKRSQRPSRCSNPTPGP

PTMs - Q9BZS1 As Substrate

Site PTM Type Enzyme
S25 Phosphorylation
K31 Acetylation
S33 Phosphorylation
T44 Phosphorylation
T115 Phosphorylation
T138 Phosphorylation
S142 Phosphorylation
K179 Acetylation
K227 Acetylation
K250 Acetylation
K252 Acetylation
K263 Acetylation
K268 Acetylation
S270 Phosphorylation
S274 Phosphorylation
S275 Phosphorylation
Y342 Phosphorylation P06239 (LCK)
K356 Ubiquitination
K393 Ubiquitination
S418 Phosphorylation
S422 Phosphorylation P11309 (PIM1)

Research Backgrounds

Function:

Transcriptional regulator which is crucial for the development and inhibitory function of regulatory T-cells (Treg). Plays an essential role in maintaining homeostasis of the immune system by allowing the acquisition of full suppressive function and stability of the Treg lineage, and by directly modulating the expansion and function of conventional T-cells. Can act either as a transcriptional repressor or a transcriptional activator depending on its interactions with other transcription factors, histone acetylases and deacetylases. The suppressive activity of Treg involves the coordinate activation of many genes, including CTLA4 and TNFRSF18 by FOXP3 along with repression of genes encoding cytokines such as interleukin-2 (IL2) and interferon-gamma (IFNG). Inhibits cytokine production and T-cell effector function by repressing the activity of two key transcription factors, RELA and NFATC2. Mediates transcriptional repression of IL2 via its association with histone acetylase KAT5 and histone deacetylase HDAC7. Can activate the expression of TNFRSF18, IL2RA and CTLA4 and repress the expression of IL2 and IFNG via its association with transcription factor RUNX1. Inhibits the differentiation of IL17 producing helper T-cells (Th17) by antagonizing RORC function, leading to down-regulation of IL17 expression, favoring Treg development. Inhibits the transcriptional activator activity of RORA. Can repress the expression of IL2 and IFNG via its association with transcription factor IKZF4 (By similarity).

PTMs:

Polyubiquitinated, leading to its proteasomal degradation in regulatory T-cells (Treg) which is mediated by STUB1 in a HSPA1A/B-dependent manner. Deubiquitinated by USP7 leading to increase in protein stability.

Phosphorylation at Ser-418 regulates its transcriptional repressor activity and consequently, regulatory T-cells (Treg) suppressive function. Dephosphorylated at Ser-418 by protein phosphatase 1 (PP1) in Treg cells derived from patients with rheumatoid arthritis. Phosphorylation by CDK2 negatively regulates its transcriptional activity and protein stability (By similarity).

Acetylation on lysine residues stabilizes FOXP3 and promotes differentiation of T-cells into induced regulatory T-cells (iTregs) associated with suppressive functions. Deacetylated by SIRT1.

Undergoes proteolytic cleavage in activated regulatory T-cells (Treg), and can be cleaved at either the N- or C-terminal site, or at both sites.

Subcellular Location:

Nucleus. Cytoplasm.
Note: Predominantly expressed in the cytoplasm in activated conventional T-cells whereas predominantly expressed in the nucleus in regulatory T-cells (Treg). The 41 kDa form derived by proteolytic processing is found exclusively in the chromatin fraction of activated Treg cells (By similarity).

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Subunit Structure:

Homodimer. Dimerization is essential for its transcriptional regulator activity. Interacts with IKZF3. Isoform 1 (via LXXLL motif), but not isoform 2, interacts with isoform 4 of RORA (via AF-2 motif). Interacts with STUB1, HSPA8 and HSPA1A/B. Interacts with PPP1CA, PPP1CB and PPP1CG. Interacts with KAT5 and HDAC7. Interacts with HDAC9 in the absence of T-cell stimulation. Interacts with USP7. Interacts with isoform 2 of ZFP90 and can form a complex with TRIM28 in the presence of isoform 2 of ZFP90. Interacts with RUNX1. Interacts with RORC. Interacts with RELA and NFATC2. Interacts with RUNX2, RUNX3 and IKZF4 (By similarity).

Family&Domains:

The fork-head DNA-binding domain is essential for its dimerization and interaction with NFATC2.

Research Fields

· Human Diseases > Immune diseases > Inflammatory bowel disease (IBD).

· Organismal Systems > Immune system > Th17 cell differentiation.   (View pathway)

References

1). Chronic low-grade inflammation is involved in TLR4 knockout-induced spontaneous obesity in aged mice. BIOMEDICINE & PHARMACOTHERAPY (PubMed: 35093760) [IF=7.5]

Application: WB    Species: Mouse    Sample:

Fig. 6. TLR4 KO affected the differentiation of Th cells in the spleen of 18 M old mice. a Relative image of the spleen and spleen index, n = 6. b Relative mRNA expression of Tbet, Gata3, Rorγt and Foxp3, n = 6. c Relative mRNA expression of important Th downstream genes in the spleen, n = 6. d Protein expression of Tbet, Gata3, Rorγt and Foxp3 and the relative Tbet, Gata3, Rorγt and Foxp3 protein levels is shown in bar graph, n = 3. e Serum levels of IL-1β, IL-6, IL-10 and TNF-α protein were measured by ELISA, n = 8. Data are presented as mean ± S.E.M.
2). Single‐cell and spatial analyses reveal the association between gene expression of glutamine synthetase with the immunosuppressive phenotype of APOE+CTSZ+TAM in cancers. Molecular Oncology (PubMed: 36587392) [IF=6.6]

Application: IF/ICC    Species: Human    Sample: CRC tissues

Fig. 7 Tissue and cellular distribution of APOE+CTSZ+TAM, GLUL+ cells, and Treg. (A, B) Multiplex immunofluorescence staining of CD68 (green), APOE (red), CTSZ (yellow), GLUL (purple), and DAPI (blue) on CRC tissue section of patient PA2203077 and patient PA2220884, scale bar 20 μm. Left: merged and single‐channel photo of the tissue section. Right: combined channel of CD68/APOE/GLUL and CD68/CTSZ/GLUL on the tissue section. (C, D) Multiplex immunofluorescence staining of CD68 (green), APOE (red), CTSZ (yellow), FOXP3 (purple), and DAPI (blue) on CRC tissue section of patient PA2203077 and patient PA2220884, scale bar 20 μm. Left: Merged and single‐channel photo of the tissue section. Right: Combined channel of CD68/APOE/FOXP3 and CD68/CTSZ/FOXP3 on the tissue section. Arrows indicate the representative regions with three immunofluorescence staining.
3). Induction of regulatory T cells and correction of cytokine dysbalance by short chain fatty acids–Implications for the therapy of psoriasis. JOURNAL OF INVESTIGATIVE DERMATOLOGY (PubMed: 32544478) [IF=6.5]

Application: IF/ICC    Species: human    Sample: PBMC

Figure 4.| Suppressive activity of psoriatic Treg is diminished compared to heathy controls and SB restores this effect. (e) Paraffin sections were stained with antihuman Foxp3 (green) and anti-human CD25 (red) antibody. Nuclear staining was performed with DAPI (blue). Scale bar=10 µm
4). Regulatory effects of miRNA-126 on Th cell differentiation and cytokine expression in allergic rhinitis. Cellular Signalling (PubMed: 35953026) [IF=4.8]
5). Anti-tumor effect of polysaccharide from Pleurotus ostreatus on H22 mouse Hepatoma ascites in-vivo and hepatocellular carcinoma in-vitro model. AMB Express (PubMed: 34855004) [IF=3.7]
6). Periodontal ligament cells under mechanical force regulate local immune homeostasis by modulating Th17/Treg cell differentiation. Clinical Oral Investigations (PubMed: 35029749) [IF=3.4]

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.